Search

Celecoxib

[A181532] It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.

Racepinephrine

Racepinephrine is a racemic mixture consisting of d-DB00668 and l-DB00668 enantiomers. Epinephrine is a non-selective α- and β-adrenergic receptor agonist. It is a bronchodilator used in the temporary relief of mild symptoms of intermitt...

Pentetrazol

Pentetrazol, also known as pentylenetetrazole, is a gamma-aminobutyric acid type A (GABA_A) receptor antagonist that was approved by the FDA until 1982.[A254437]

Dostarlimab

[L33340] This indication was granted full FDA approval on February 10, 2023.[L45161] Dostarlimab-gxly was granted second accelerated approval for the treatment of solid tumours in the same month. … In April 2021, dostarlimab was granted accelerated approval by the FDA - as GlaxoSmithKline's dostarlimab-gxly (Jemperli) - for the treatment of adult patients with recurrent or advanced mismatch repair

Atezolizumab

[L7489] Atezolizumab was granted FDA approval on 18 October 2016.

Besifloxacin

FDA approved on May 28, 2009.

Semaglutide

[L41335] On May 31, 2023, the FDA issued a warning regarding the use of compounded semaglutide after receiving adverse event reports. … Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017.[L8681] The tablet formulation was approved for oral administration in September 2019.

Omadacycline

Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over t...

Chromous sulfate

Fluticasone furoate

Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label][F4364]. Fluticasone furoate was first approved in 2007[L5965].